NIKI (Niki BioSolutions) Common Stock: $0.00 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NIKI Niki BioSolutions Inc NIKI
56 GF Score
Price $9.54
GF Value $11.69
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is Niki BioSolutions Common Stock?

Niki BioSolutions NIKI +11.06% 56 Common Stock is $0.00 Mil as of Dec. 2025. GuruFocus rates NIKI with a GF Score™ of 56/100 and a GF Value™ of $11.69 (Modestly Undervalued). The stock has 1 warning sign investors should review.

Niki BioSolutions Common Stock Historical Data

* Premium members only.

The historical data trend for Niki BioSolutions's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Niki BioSolutions Common Stock Chart

Niki BioSolutions Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Common Stock
Get a 7-Day Free Trial Premium Member Only 35.64 35.71 0.00 0.00 0.00

Niki BioSolutions Quarterly Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Sep24 Dec24 Jun25 Sep25 Dec25
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
NIKI
56GF Score
Niki BioSolutions Inc NIKI
Common Stock is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Niki BioSolutions Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Frequently Asked Questions Learn more about Common Stock →
What does a Common Stock of $0.00 Mil mean?
Niki BioSolutions (NIKI) has a Common Stock of $0.00 Mil as of Dec. 2025. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Niki BioSolutions and its competitors.
Is Niki BioSolutions' Common Stock too high?
Niki BioSolutions' current Common Stock is $0.00 Mil. Overall, Niki BioSolutions has a GF Score™ of 56/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Niki BioSolutions' Common Stock compare to LABT and NCNA?
Niki BioSolutions' Common Stock of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Common Stock for a Biotechnology company?
A good Common Stock depends on the Biotechnology industry context. However, Common Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Common Stock mean?
A high Common Stock can signal that a stock is expensive relative to its fundamentals. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Niki BioSolutions and its competitors. Niki BioSolutions's current Common Stock is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Niki BioSolutions stock overvalued right now?
Based on GuruFocus' analysis, Niki BioSolutions (NIKI) is currently considered Modestly Undervalued. The stock's GF Value™ is $11.69, compared to a current price of $9.54 — trading 18.4% below its estimated fair value. The current Common Stock is $0.00 Mil. Niki BioSolutions' overall GF Score™ is 56/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Common Stock calculated?
Common Stock is calculated from a company's financial statements. For Niki BioSolutions (NIKI), the current Common Stock is $0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Niki BioSolutions (NIKI) Overvalued in 2026?

Based on GuruFocus' analysis, Niki BioSolutions stock appears to be undervalued. The current stock price of $9.54 is trading 18.4% below its estimated GF Value™ of $11.69. GuruFocus considers Niki BioSolutions to be Modestly Undervalued.

Key valuation signals for NIKI:

  • Common Stock: $0.00 Mil
  • GF Value™: $11.69 vs. price of $9.54 (18.4% below fair value)
  • GF Score™: 56/100 with 1 warning sign

No single metric tells the full story. See the NIKI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Niki BioSolutions Business Description

Address 17 Hanover Square, London, GBR, W1S 1BN
Aptorum Group Ltd is a clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. Aptorum's project pipeline includes SACT-1, a repurposed drug for the treatment of neuroblastoma, and ALS-4, a small molecule for the treatment of bacterial infections caused by Staphylococcus aureus, including but not limited to Methicillin-resistant Staphylococcus aureus (MRSA). Substantially all of the company's revenues are derived from within Hong Kong.
56GF Score

Get the complete analysis for NIKI

Common Stock is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$9.54
Price
$11.69
GF Value